MarketCap
Facebook
X
Telegram
PerkinElmer Accounts Receivables | PKI
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 783 M | 661 M | 662 M | 738 M | 1.18 B | - | 745 M | 633 M | 552 M | 439 M | - | 471 M | 470 M | 457 M | 357 M | 320 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 320 M | 605 M |
Quarterly Accounts Receivables PerkinElmer
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 745 M | 691 M | 632 M | 680 M | 661 M | 617 M | 632 M | 602 M | 597 M | 589 M | 633 M | 645 M | 627 M | 587 M | 613 M | 541 M | 932 M | 942 M | 1.18 B | 948 M | 993 M | 979 M | - | 798 M | 709 M | 626 M | 745 M | 725 M | 725 M | 725 M | 633 M | 633 M | 633 M | 633 M | 552 M | 552 M | 552 M | 552 M | 415 M | 443 M | 436 M | 437 M | - | 414 M | 426 M | 415 M | 471 M | 471 M | 471 M | 471 M | 467 M | 467 M | 467 M | 470 M | 457 M | 457 M | 457 M | 457 M | 357 M | 360 M | 383 M | 345 M | 320 M | 324 M | 365 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 B | 320 M | 585 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Soleno Therapeutics
SLNO
|
28.2 M | - | - | $ 2.69 B |  USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
3.91 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
552 M | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
854 M | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.04 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
402 M | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
778 M | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
297 M | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
403 M | $ 50.36 | -0.98 % | $ 10.9 B |  Niderland |
 |
RadNet
RDNT
|
200 M | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
127 K | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
1.4 M | - | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
16.5 M | $ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
8.9 B | $ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
VolitionRx Limited
VNRX
|
318 K | $ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
829 M | $ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
10.9 M | $ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
138 M | $ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
3.4 B | $ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
6.27 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
13.3 M | - | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
782 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K |  Israel |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
100 K | - | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
2.5 M | - | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
47.2 M | - | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
1.22 B | $ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
1.49 B | $ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
43.4 M | $ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
173 K | $ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
9.04 M | $ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
5.2 M | $ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
128 M | $ 10.61 | -0.66 % | $ 707 M | USA |